Bristol hep C drug helps cure 97 percent of HIV coinfected patients: study

February 26, 2015 8:20 PM

14 0

(Reuters) - Ninety-seven percent of hepatitis C patients also infected with HIV were cured of the liver-destroying virus after 12 weeks of treatment with Bristol-Myers Squibb's daclatasvir and Gilead Sciences' Sovaldi, according to data from a study presented on Thursday.

The results could help put Bristol's hepatitis C program back on track in the United States, following a setback last year.

Read more

To category page